ERBB2 and breast carcinoma: c-MET overexpression was observed in 4.7% (17/358), 3.8% (4/104), 7.1% (7/98), and 13.6% (22/162) of the primary sites in HR+/HER2−, HR+/HER2+, HER2-enriched, and Triple-negative breast cancer samples, respectively (Additional file 7: Table S6).